OptimizeRx (OPRX) Change in Accured Expenses (2010 - 2026)

OptimizeRx (OPRX) has 17 years of Change in Accured Expenses data on file, last reported at -$8.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 1035.48% year-over-year to -$8.0 million; the trailing twelve-month figure through Mar 2026 stood at -$5.5 million (down 341.03% YoY), and the FY2025 full-year result was $3.4 million, up 220.42% from the prior year.
• Change in Accured Expenses fell to -$8.0 million in Q1 2026, from $1.5 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $3.3 million in Q2 2025 to a low of -$8.0 million in Q1 2026.
• A 5-year average of -$150609.8 and a median of $26282.0 in 2022 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses surged 6010.65% in 2023 and plunged 1035.48% in 2026, its largest moves.
• Tracing OPRX's Change in Accured Expenses over 5 years: stood at $936323.0 in 2022, then fell by 15.2% to $794000.0 in 2023, then surged by 284.13% to $3.0 million in 2024, then plunged by 52.1% to $1.5 million in 2025, then plunged by 646.82% to -$8.0 million in 2026.
• Business Quant data shows OPRX's Change in Accured Expenses at -$8.0 million in Q1 2026, $1.5 million in Q4 2025, and -$2.2 million in Q3 2025.